PAVmed

PAVM

Market cap $9.21M

Overview Fund Activity

0.4201 USD

-0.0078

1.82%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.82%

5 days

-10.62%

1 month

-5%

3 months

-38.07%

6 months

-31.14%

Year to date

-34.36%

1 year

-75.58%

5 years

-98.47%

10 years

-99.78%

About: PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.

Employees: 107

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding

Funds holding: 31 [Q1] → 31 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.19% less ownership

Funds ownership: 7.36% [Q1] → 7.17% (-0.19%) [Q2]

16% less capital invested

Capital invested by funds: $873K [Q1] → $735K (-$138K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 6 articles about PAVM published over the past 30 days

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.00 per share.

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share.

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering.

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m.

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced Lishan Aklog, M.D.

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the technology NEW YORK , Aug. 26, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT)—could allow for a more efficient and effective alternative to traditional biopsies.

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, relaunched development of implantablephysiological monitor, and initiated integration steps to launch commercial phase withOSU-The James Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK , Aug. 14, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended June 30, 2025. Conference Call and Webcast The webcast will take place on Thursday, August 14, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for EsoGuard to be held on September 4 Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK , Aug. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended June 30, 2025. Conference Call and Webcast The webcast will take place on Wednesday, August 13, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

Lucid Diagnostics to Participate in Upcoming Investor Conferences

NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

See News Rankings

Charts implemented using Lightweight Charts™